Catalyst
Key milestones include the determination of the recommended dose for Phase 2 and the safety profile of NKT5097 as monotherapy and in combination with endocrine therapy.
Date
June 28, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.